YHB Investment Advisors Inc. Has $981,000 Position in Bristol-Myers Squibb (NYSE:BMY)

YHB Investment Advisors Inc. trimmed its stake in Bristol-Myers Squibb (NYSE:BMY) by 2.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,956 shares of the biopharmaceutical company’s stock after selling 423 shares during the quarter. YHB Investment Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $981,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. ESL Trust Services LLC bought a new stake in Bristol-Myers Squibb in the 1st quarter valued at about $27,000. ORG Wealth Partners LLC bought a new stake in shares of Bristol-Myers Squibb during the third quarter valued at approximately $34,000. LGT Financial Advisors LLC raised its position in shares of Bristol-Myers Squibb by 42.7% during the second quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 227 shares during the period. Redmont Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the 1st quarter worth $47,000. Finally, MFA Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the 2nd quarter valued at $39,000. 76.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on BMY. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, October 18th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $48.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, September 23rd. Barclays lifted their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. Sanford C. Bernstein assumed coverage on Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 target price on the stock. Finally, TD Cowen lifted their target price on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $53.20.

Bristol-Myers Squibb Trading Up 0.6 %

NYSE:BMY opened at $53.06 on Thursday. The firm’s 50 day moving average is $50.63 and its 200 day moving average is $46.39. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $56.77. The stock has a market capitalization of $107.56 billion, a PE ratio of -17.12, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm had revenue of $12.20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. During the same quarter in the prior year, the firm earned $1.75 EPS. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. Sell-side analysts expect that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.52%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.